GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2597124&ei=kXKaUvDOH7Hr0QGFIA&usg=AFQjCNHdtLACzy_iPD7Agyu8n4ZYCj551A
U.S. FDA Approves Gilead Sciences Inc's Stribild
Monday, 27 Aug 2012 05:10pm EDT
Gilead Sciences Inc announced that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults. Stribild, referred to as Quad prior to FDA approval, combines four compounds in one daily tablet: elvitegravir, an integrase inhibitor; cobicistat, a pharmacoenhancing agent; emtricitabine and tenofovir disoproxil fumarate. 
